Involvement of TRPV1 and MOR-NMDAR complex on the antiallodynic effect of LMH-2, a sigma-1 receptor antagonist, in mouse model of diabetic neuropathy - a behavioral approach
Authors:
- Rosa Ventura-MartínezRosa Ventura-Martínez
- Guadalupe Esther Ángeles-LópezGÁGuadalupe Esther Ángeles-López
- Tania Domínguez-PáezTDTania Domínguez-Páez
- Gabriel Navarrete-VázquezGabriel Navarrete-Vázquez
- Wendy Arratia-DamiánWAWendy Arratia-Damián
- Maria Eva González-TrujanoMGMaria Eva González-Trujano
- Myrna Déciga-CamposMyrna Déciga-Campos
Open Access
- 23 April 2025
- journal article
- research article
- Published by Springer Nature in Pharmacological Reports
- Vol. 77 (4) , 1011-1023
Abstract
Background: Recently, the antinociceptive effect of LMH-2, a σ1 receptor antagonist, has been reported in diabetic mice with neuropathic pain. However, the mechanism by which this effect is produced is not completely clear. In this study, we explored the involvement of TRPV1 and the MOR-NMDAR complex in the antiallodynic effect of LMH-2 in hyperglycemic mice with neuropathic pain. Methods: Hyperglycemia was induced in mice by administering streptozotocin-nicotinamide. Four weeks later, once neuropathic pain was established, the antiallodynic effect of LMH-2 (56.2 mg/kg) was evaluated using the up-down method with the von Frey filaments, both in the absence and the presence of capsazepine (8 mg/kg, ip), naloxone (NLX, 1 mg/kg, ip), NMDA (0.4 nM/10 µL, it), or their co-administration (NLX-NMDA). Gabapentin was used as positive control. Results: Pretreatment with NLX did not alter the antiallodynic effect of LMH-2 in the up-down method with the von Frey filaments in hyperglycemic mice, whereas NMDA significantly reduced it. The addition of NLX to NMDA (NLX-NMDA) did not modify the effect of NMDA alone on the antiallodynic activity of LMH-2. Additionally, capsazepine completely blocked the antinociceptive effect of LMH-2 in hyperglycemic mice. Molecular docking analysis suggested a potential interaction between LMH-2 and TRPV1. Moreover, a higher dose of LMH-2 did not cause mortality or damage in healthy mice. Conclusion: These results suggest the potential utility of LMH-2 in the treatment of diabetic neuropathy and highlight a key role for TRPV1 in LMH-2’s antiallodynic mechanism, along with a possible, albeit limited, interaction with the MOR/NMDA complex.Keywords
Funding Information
- Dirección General de Asuntos del Personal Académico, Universidad Nacional Autónoma de México (UNAM-PAPIIT-IN201723)
- Consejo Nacional de Humanidades, Ciencias y Tecnologías (CONACYT-FOP16-2021-01/319379, CF-2023-I-822)
- Secretaría de Investigación y Posgrado, Instituto Politécnico Nacional (SIP-IPN 20240205)
This publication has 50 references indexed in Scilit:
- Presynaptic NMDA receptors control nociceptive transmission at the spinal cord level in neuropathic painCellular and Molecular Life Sciences, 2019
- The Sigma-1 Receptor Antagonist, S1RA, Reduces Stroke Damage, Ameliorates Post-Stroke Neurological Deficits and Suppresses the Overexpression of MMP-9Molecular Neurobiology, 2017
- Pharmacological Modulation of the Sigma 1 Receptor and the Treatment of Pain2017
- Sigma-1 Receptor Antagonists: A New Class of Neuromodulatory Analgesics2017
- Sigma-1 receptor inhibition reverses acute inflammatory hyperalgesia in mice: role of peripheral sigma-1 receptorsPsychopharmacology, 2014
- The antagonistic effect of the sigma 1 receptor ligand (+)-MR200 on persistent pain induced by inflammationInflammation Research, 2013
- New potent biphalin analogues containing p-fluoro-l-phenylalanine at the 4,4′ positions and non-hydrazine linkersAmino Acids, 2010
- Antagonism by haloperidol and its metabolites of mechanical hypersensitivity induced by intraplantar capsaicin in mice: role of sigma-1 receptorsPsychopharmacology, 2009
- Antinociceptive effects of haloperidol and its metabolites in the formalin test in micePsychopharmacology, 2005
- Diabetic Neuropathy1985